Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
1.530
-0.160 (-9.47%)
At close: Nov 1, 2024, 4:00 PM
1.560
+0.030 (1.96%)
After-hours: Nov 1, 2024, 5:45 PM EDT
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for TSHA stock have an average target of 6.38, with a low estimate of 5.00 and a high estimate of 8.00. The average target predicts an increase of 316.99% from the current stock price of 1.53.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 14, 2024.
Analyst Ratings
The average analyst rating for TSHA stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 4 | 5 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 10 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $7 → $6 | Strong Buy | Maintains | $7 → $6 | +292.16% | Aug 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +357.52% | Aug 13, 2024 |
| Needham | Needham | Strong Buy Maintains $7 → $6 | Strong Buy | Maintains | $7 → $6 | +292.16% | Aug 12, 2024 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +357.52% | Jul 26, 2024 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +357.52% | Jul 23, 2024 |
Financial Forecast
Revenue This Year
8.54M
from 15.45M
Decreased by -44.76%
Revenue Next Year
5.34M
from 8.54M
Decreased by -37.43%
EPS This Year
-0.39
from -0.96
EPS Next Year
-0.43
from -0.39
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 19.0M | 15.8M | 10.5M | ||
| Avg | 8.5M | 5.3M | 5.3M | ||
| Low | 4.4M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 23.0% | 84.5% | 96.6% | ||
| Avg | -44.8% | -37.4% | -1.0% | ||
| Low | -71.5% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.37 | -0.36 | -0.37 | ||
| Avg | -0.39 | -0.43 | -0.45 | ||
| Low | -0.42 | -0.57 | -0.63 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.